Circulating Plasma MicroRNAs As Diagnostic Markers for NSCLC

Jinpao Hou¹, Fei Meng¹, Lawrence W. C. Chan¹*, William C. S. Cho² and S. C. Cesar Wong¹

¹Department of Health Technology and Informatics, Hong Kong Polytechnic University, Hong Kong, Hong Kong,
²Department of Clinical Oncology, The Queen Elizabeth Hospital, Kowloon, Hong Kong, Hong Kong

Lung cancer is the most common cause of cancer deaths all over the world, in which non-small cell lung cancer (NSCLC) accounts for ~85% of cases. It is well known that microRNAs (miRNAs) play a critical role in various cellular processes, mediating post-transcriptional silencing either by mRNA degradation through binding the 3′ UTR of target mRNA or by translational inhibition of the protein. In the past decade, miRNAs have also been increasingly identified in biological fluids such as human serum or plasma known as circulating or cell-free miRNAs, and may function as non-invasive diagnostic markers for various cancer types including NSCLC. Circulating tumor cells (CTCs) are those cells that are shed from solid tumors and then migrate into the circulation. However, reports concerning the roles of CTCs are quite rare, which may be attributed to the difficulties in the enrichment and detection of CTCs in the circulation. Although, there have been reassuring advances in identifying circulating miRNA-panels, which are assumed to be of diagnostic value in NSCLC early stage, some issues remain concerning the reliability of using miRNA panels as a diagnostic tool for NSCLC. In the current review, we are aiming at providing insights into the miRNAs biology, the mechanisms of miRNAs release into the bloodstream, cell-free miRNAs as the diagnostic markers for NSCLC and the current limitations of CTCs as diagnostic markers in NSCLC.

Keywords: NSCLC, circulating miRNAs, miRNA panel, diagnostic value, CTCs detection

INTRODUCTION

Lung cancer is the most common cause of cancer deaths in men and the second leading cause of cancer deaths in women (Jemal et al., 2010; Ozretić et al., 2012). WHO has shown that lung cancer strikes over 1,605,000 people each year and explains 18.2% of all cancer-related deaths (http://globocan.iarc.fr). There are two types of lung cancer: small cell lung cancer (SCLC) that is a more aggressive type and accounts for 15% of cases, and non-small cell lung cancer (NSCLC), which comprises small squamous cell carcinoma (SCC), adenocarcinoma (AD) and large cell carcinoma (LCC). Remarkably, NSCLC alone accounts for 85% of cases (Travis et al., 2011; Wood et al., 2012). With respect to NSCLC, the main reason for the current high mortality is its late diagnosis and poor prognosis. According to the data from National Cancer Institute, 55% of cases are diagnosed at an advanced stage and over half of the lung cancer patients die within one year of diagnosis (SEER Cancer Statistics Review). In addition, the 5-year survival rates vary from 67% in Stage IA to 39% in Stage IIB, and for patients who were at inoperable advanced stage, the 5-year survival rates even hardly reach 3.3% (Scagliotti et al., 2003; Jemal et al., 2004). Traditional diagnosis of NSCLC tends to be based on either computed tomography (CT) scans or chest X-ray following...
Abbreviations: MVB, Microvesicular bodies; AGO, Argonaute proteins; MiRISC, miRNA-induced silencing complex; 5′ UTR, 5′untranslated region; Ldbr, lariat debranching enzyme; KSRP, KH-type splicing regulatory protein; hnRNP A1, heterogeneous nuclear ribonucleoprotein A1.
found 5′ and 3′ tailed mirtrons that are very similar to conventional mi-trons. The difference between them is that following debranching, tailed mirtrons contain a single-stranded tail on either 5′ or 3′ of the pre-miRNA-like hairpins, which needs to be trimmed by an exonuclease known as RNA exosome to produce pre-miRNAs for Dicer cleavage (Okamura et al., 2008; Westholm and Lai, 2011). In effect, pre-miRNAs derived from both conventional miRNAs and mirtrons or tailed mi-trons are further exported by Exportin-5 into the cytoplasm, where they are subject to Dicer cleavage to generate miRNA duplex (Figure 1).

Several RNA-binding proteins are involved in a select group of miRNA biosynthesis, acting either as “co-activators” or “co-repressors” for the processing of miRNA precursors. Among them are the three most important proteins: Cell lineage abnormal 28 (Lin-28), KH-type splicing regulatory protein (KSRP) and heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1). Numerous studies have demonstrated that human paralogs Lin-28a and Lin-28b can prevent the maturation of let-7 by interacting with pri- or pre-let-7 via the terminal loop (TL) elements to inhibit their processing by Drosha and Dicer (Choudhury and Michlewski, 2012; Huang, 2012; Mayr and Heinemann, 2013). Intriguingly, Lin-28 protein levels are found to be much higher in undifferentiated cells and the early stages of embryonic development, while mature let-7 miRNAs are absent despite the existence of pre-let-7 (Choudhury and Michlewski, 2012). By contrast, KSRP, also known as FBP2, are shown to act as an auxiliary protein to promote the maturation of select miRNAs including let-7 by binding to TL elements and interacting with Drosha and Dicer, which is similar to the way Lin-28 bind to miRNA precursors (Gherzi et al., 2010). In addition, hnRNP A1 is one of the most abundant members in the protein family of hnRNP. Unlike lin-28 or KSRP, hnRNP A1 either promotes or inhibits the maturation of miRNAs via different mechanisms according to the miRNA precursor it interacts with. For example, Michlewski G and co-workers showed that hnRNP A1 is required for the processing of pri-miR-18a by binding to its TL element to induce stem-loop structure rearrangement, thus facilitating more effective Drosha cleavage (Michlewski et al., 2008; Choudhury and Michlewski, 2012). However, these authors also have revealed that hnRNP A1 binds to the TL element of pri-let-7a to inhibit Drosha cleavage, thus preventing the processing of pri-let-7a. Most interestingly, they also confirmed the same sequence in the TL element of pri-let-7a is the target of KSRP and proposed that hnRNP A1 and KSRP play antagonistic roles in the maturation of let-7a (Michlewski and Cáceres, 2010). The roles of these protein factors in the processing of miRNA precursors are shown in Figure 1.

POSSIBLE MECHANISMS OF MiRNA ENTERING INTO THE CIRCULATION

As non-invasive serological markers of tumors, circulating miRNAs are first identified concurrently by two groups in 2008. Mitchell et al. have demonstrated that circulating miRNAs levels in human plasma remain stable even when plasma is subjected to prolonged incubation at room temperature. In addition, they showed that circulating miRNAs are resistant to multiple freeze-thaw cycles. Furthermore, they used a mouse model to reveal that extracellular miRNAs arising from human prostate cancer xenografts enter the circulatory system (Mitchell et al., 2008). By Solexa sequencing, Chen et al. (2008) found that compared to healthy donors, 28 miRNAs species are missing and 63 new miRNA species are detected in lung cancer patients, suggesting that human serum might contain miRNA signatures of the ongoing disease (Chen et al., 2008). These two studies established the concept that one can diagnose cancers based on specific cell-free miRNA signatures. In the meantime, a number of intriguing questions have been posed, among which are the routes of miRNA release into the circulation.

During the past decade, several research groups have found that circulating miRNAs can be packaged into some types of membrane-bound vesicles such as microvesicular bodies (MVB) or exosomes. Given the remarkable stability of circulating miRNA, for several years, the predominant view was that the vast majority of cell-free miRNAs were released from cells in vesicles (Valadi et al., 2007; Zernecke et al., 2009; Collino et al., 2010). However, others have revealed that cell-free miRNAs also exist in vesicle-free forms associating with protein complexes including high and low density lipoproteins and RNA-binding proteins (Wang et al., 2010; Arroyo et al., 2011; Vickers et al., 2011). For instance, Arroyo JD have shown that Argonaute2 (AGO2), the key effector protein of miRNA-mediated silencing, is present in human plasma and serve as a significant carrier of circulating miRNAs in plasma as shown in Figure 1. They also found that potentially 90% of circulating miRNAs are present in vesicle-free form, which suggest that circulating miRNA biomarker analysis based only on exosome purification might be ineffective for miRNA biomarkers that circulate as nonexosomal AGO2 complexes (Arroyo et al., 2011). Additionally, Vicker KC et al. have demonstrated that high-density lipoprotein particles (HDL) transport endogenous miRNAs and deliver them to recipient cells, the process of which is regulated by neutral sphingomyelinase and dependent on scavenger receptor class B type I (Vickers et al., 2011). Moreover, vesicle-associated miRNAs versus vesicle-free miRNAs may originate from different cell types and indicate cell-type specific miRNA release mechanisms. For example, miR-122, a liver-specific miRNA, circulates only in protein-associated form, suggesting that hepatocytes release miR-122 via protein carrier pathway (Chang et al., 2004). By contrast, miRNAs primarily present in membrane-bound vesicles, such as let-7a, may originate from cell types that generate vesicles (Arroyo et al., 2011). However, the relative abundance of vesicle-derived miRNAs versus vesicle-free miRNAs for any given miRNA species remains to be explored.

CIRCULATING MiRNAs AS DiAGnostic BIoMARKERS OF NsCLC

The non-invasiveness, stability and reproducibility make circulating miRNAs an ideal diagnostic marker in oncology and hold great promise for clinical applications. Since circulating
miRNAs were first identified in human plasma in 2008, a great many of studies have been aiming at identifying a reliable diagnostic tool by investigating the differential expression of circulating miRNAs between NSCLC patients and healthy controls or patients harboring benign tumors. For instance, Lihong Fan et al. have demonstrated that a predictive model combining serum miR-15b-5p, miR-16-5p, miR-20a-5p can be used to discriminate the early stage of NSCLC cases from healthy subjects (Fan et al., 2015). Reassuringly, the fact that this study applied two different methods (RT-qPCR and Nano-quantum dots microarray) to identify the same differential expression of serum miRNAs, which may have improved the sensitivity and reproducibility of the results. Additionally, Li Y et al. have isothermally sensitively detected lung cancer-associated serum miR-486-5p through hairpin probe-based rolling circle amplification (HP-RCA) with superhigh sensitivity (Li et al., 2013). In practice, miR-486-5p has been shown to be downregulated in both the primary cancer and the serum of NSCLC patients in several independent research groups (Volinia et al., 2006; Boeri et al., 2011; Shen et al., 2011), which suggests this miRNA might serve as a tumor suppressor involved in multiple signaling circuits in NSCLC and thus deserves highly attention in future study. Furthermore, a 34-miRNA panel in serum has been identified in patients at the early stage of NSCLC in a group of asymptomatic high-risk subjects with up to 80% accuracy (Bianchi et al., 2011). The signature obtained in this study allows the diagnosis of asymptomatic patients instead of symptomatic ones diagnosed by other signatures in many previous studies. Most importantly, it is specific for lung cancer compared with breast cancer. However, the researchers of this study may well test for the specificity of this signature in other more cancer types other than breast cancer before its clinical application. Moreover, using three different analytical methods, A. Markou and colleagues identified an eight miRNA-panel which can be used for discriminating cancerous tissues from non-cancerous ones in NSCLC patients. By contrast, only

![Diagram of miRNA biosynthesis through canonical and non-canonical pathways and the mechanisms of miRNA release into the bloodstream](image)
three of these miRNAs (miR-30e-5p, miR-21 and miR-10a) are differentially expressed in NSCLC plasma specimens compared to that from healthy plasma, suggesting miRNA profiles in the circulation may not necessarily reflect exactly those in tumor tissues (Markou et al., 2013). However, an earlier report have showed that miRNA footprints did not show significant difference between circulating exosome-derived miRNAs and the tumoral miRNAs profiles using 4 lung cancer tissues and their corresponding plasma samples (Rabinowits et al., 2009). This contradiction between these two studies may be attributed to two factors: one is that the internal control gene used for the normalization of miRNA expression may vary between different research groups; the other is that circulating miRNAs do not exist only in exosomes as mentioned earlier, most of them are shown to be associated with protein complexes. Most importantly, only 4 lung cancer tissues used for the study are not enough to represent a reliable result.

In the past two years, a vast number of efforts have been made to identify circulating miRNA panels for NSCLC early diagnosis. However, many of these studies remain to be validated given the inconsistency of reference controls used for the normalization and of the materials such as exosomes, serum and whole blood used for RNA isolation. For instance, Magdalena B. Wozniak and colleagues showed that a 24-miRNA panel alone could distinguish lung cancer patients from healthy controls with an AUC of 0.92, and they also revealed that this diagnostic power can be further enhanced by adding factors such as age, sex and smoking status into this model (Wozniak et al., 2015). Similarly, 6 cell-free miRNAs (200b, 429, 205, 125b, 34b, 203) have also been validated with an even higher abundance in the serum of NSCLC patients compared to healthy subjects (Halvorsen et al., 2016). However, a common problem in these two studies is that the authors have chosen U6 as the internal control for the normalization when analyzing the miRNAs profiles, which may be inaccurate as U6 has been reported to be not a suitable endogenous control for the quantification of cell-free miRNAs (Benz et al., 2013; Xiang et al., 2014). Therefore, it is conceivable that the conclusions obtained from those studies should be interpreted with caution. In addition, Silva et.al reported that the levels miR-30e-3p, let-7f and miR-20b, were downregulated in the plasma vesicles of NSCLC cases compared with healthy controls (Silva et al., 2011). Another similar study showed that a panel of miRNAs (30b, 30c, 103, 122, 195, 203, 221, 222) in exosomes from the plasma displayed significantly differential expression between NSCLC cases and healthy donors, which might suggest the possibility that miRNAs signatures from patient exosomes could alone represent the status of ongoing disease (Giallombardo et al., 2016). However, these studies might not be complete as researchers focused only on vesicle-associated miRNAs, such as exosomes, probably missing the differential expression of vesicle-free miRNAs that may represent a larger proportion of miRNAs in the circulation and thus producing an inaccurate result. Most of the reported results identifying circulating miRNA panels as diagnostic biomarkers in the last two years are summarized in following Table 1. As shown in the table, different miRNA-panels have been identified by different research groups. Actually, some above mentioned factors such as various biological materials and different internal controls used may account for this phenomenon.

Although, there do exist some concerns about current studies of circulating miRNAs, some critical miRNAs as tumor suppressors or oncogenes are of great value to develop miRNA-based strategy for lung cancer therapy and therefore should be prioritized to further studies with respect to their diagnostic power. Among these critical miRNAs, miR-21 is a known to be an “oncomir” and is commonly overexpressed in cancers including lung, breast and colorectal cancer (Ma et al., 2014). For example, Si ML and colleagues showed that miR-21 inhibition suppresses tumor growth in xenograft mouse model and increases cell apoptosis that is associated with downregulation of bcl-2 expression in breast cancer (Si et al., 2007). Also, higher expression of miR-21 and miR-155 in both tumor tissues and serum can predict recurrence and poor survival in NSCLC (Yang et al., 2013). This may suggest that overexpression of circulating miR-21 holds great prognostic potential in NSCLC. Another aspect about miR-21 is that it influences response to chemotherapy in several tumor types and thus can act as a therapeutic target for overcoming drug resistance in cancers. For instance, a recent study has revealed that antisense inhibition of miR-21 or miR-221 sensitizes the effects of Gemcitabine, a chemotherapeutic treatment of pancreatic cancer (Park et al., 2009). By contrast, let-7 family miRNAs are known as tumor suppressors and down-regulation of let-7 expression has been demonstrated in breast, prostate, ovarian and lung cancers (Boyerinas et al., 2010). Dejuan Kong et al. have provided evidence that let-7 loss mediates up-regulation of EZH2 and contributes to PCa aggressiveness, which can be attenuated by B-DIM, a potent agent in inhibiting the growth of Pca cells (Kong et al., 2012). In addition, numerous studies have revealed that let-7 acts as a promising therapeutic target for lung cancer. For example, Trang’s group have shown that systematical delivery of synthetic let-7 mimic or miR-34a into lung tumor-bearing mice results in significant tumor regression compared to the delivery of a miRNA control (Trang et al., 2011). Overall, since current studies on the roles of miR-21 and let-7 family in various cancer types have mainly focused on tumor tissues, circulating miR-21 and let-7 in plasma warrant further validation before applying them as biomarkers for the early diagnosis of cancers including NSCLC.

**CURRENT LIMITATIONS ON CTCs AS DIAGNOSTIC MARKERS OF NSCLC**

CTCs are tumors cells which are released from solid tumors, and then migrate into the circulation and play a critical role in tumor metastasis. However, CTCs are extremely rare, and they can be detected at a low frequency of 1 CTCs per 10⁶-10⁷ leukocytes (Young et al., 2012). Initially, CTCs were considered as non-leukocytic cells with epithelial origin since they have been detected in various epithelial cancers such as breast cancer, lung cancer and colon cancer (Allard et al., 2004). Consequently, epithelial marker-based methods for the detection of CTCs have been widely used (Hardingham et al., 1993; Liljefors et al., 2005).
Nevertheless, recent studies have shown that the morphological characteristics of CTCs have yet to be well defined and may vary according to tumor stages (Parkinson et al., 2012). Overall, more clear phenotypes of CTCs as a “liquid biopsy” remain to be explored in future study.

As a “liquid biopsy,” current studies on CTCs as a biomarker of NSCLC have been limited to its enrichment and detection as well as its relation to NSCLC prognosis. For instance, Laura Muinelo-Romay and colleagues found that patients with CTCs >5 are assumed to correlate with poorer prognosis based on CTCs counts using CellSearch technology (Muinelo-Romay et al., 2014). Another group have isolated CTCs by cell size filtration and shown that CTCs can be identified in two-thirds of patients at advanced stage of NSCLC at diagnosis, suggesting that CTCs counts may reflect the ongoing disease status of NSCLC (Mascalchi et al., 2016).

However, less progress has been made in the field of CTCs as an ideal biomarker for NSCLC diagnosis, and this may result from several aspects. For one thing, various techniques for CTCs enrichment and later detection have been developed which base either on physical properties such as size, density and electric charges, or on biological properties such as the expression of CTCs surface marker (Alix-Panabieres and Pantel, 2013), among which the most widely used method relies on the epithelial protein, namely, Epithelial cell adhesion molecule (Ep-CAM) for the CTCs enrichment (Allard et al., 2004; Harb et al., 2013; Haus et al., 2014). However, Hanssen A et al. reported that the expression Ep-CAM may be downregulated in CTCs experiencing epithelial-to-mesenchymal transition (EMT), which raises the concern that this Ep-CAM based CTCs enrichment method may lose EMT-associated CTCs (Hanssen et al., 2016). Additionally, another group, Yingchun Man et al. have developed four CTCs markers (CK7, CLCA2, HMMR and hTERT) to detect CTCs, which significantly improves the specificity and sensitivity of CTC detection (Man et al., 2014). Intriguingly, by miRNA in situ hybridization, Francisco G. Ortega et al. have identified miR-21 within CTCs as a marker used for detecting CTCs displaying an EMT phenotype (Ortega et al., 2015). We can infer that miR-21 may be function as an oncomir implicated in tumor metastasis. In a nutshell, whether epithelial maker-dependent or -independent approach is more sensitive and specific in CTCs enrichment and detection remains to be explored. For another thing, CTCs counts alone may not fully represent the ongoing NSCLC status especially at a very early stage. This concept is clearly intelligible given that several results have shown CTCs heterogeneity as a diagnostic marker by identifying different CTCs subpopulations. In a research reported by Wu et al. (2015), three CTCs subpopulations, epithelial CTCs, biophenotypic epithelial/mesenchymal CTCs and mesenchymal CTCs, were identified using epithelial-to-mesenchymal transition markers, which is useful to identify the more aggressive CTC phenotypes and thus facilitates the determination of clinical practice.

**DISCUSSION**

NSCLC diagnosis, especially at early stage is in great demand in clinical practice. Conventional diagnostic applications relying on tissue biopsy either through computed tomography scans or chest X-ray have remarkable limitations given their low sensitivity and invasiveness as well as tissue unavailability. Consequently, a novel, reliable and reproducible diagnostic biomarker is badly needed to obtain an earlier and more accurate diagnosis result.

Circulating miRNAs in biological fluids, especially in human plasma or serum, have emerged as a non-invasive diagnostic marker for NSCLC. In the past five years, studies in this field have identified different miRNA panels in the circulation with higher sensitivity plus higher specificity in early NSCLC diagnosis, which might be preferable compared to any single miRNA used for NSCLC diagnosis. In addition, several factors

### TABLE 1 | Circulating miRNAs as diagnostic markers for NSCLC.

| Significantly-expressed miRNAs | Scope | Sample | Technique | Normalization | References |
|-------------------------------|-------|--------|-----------|--------------|-----------|
| let-7c, miR-152 (down)        | 120 NSCLCs vs. 360 HCs | Plasma | qRT-PCR | U6 | Dou et al., 2016 |
| miR-16-5p, miR-17b-5p, miR-19-3p, miR-20a-5p, miR-92-3p (down) | Training set: 94 NSCLCs vs. 58 HCs, Validation set: 70 NSCLCs vs. 54 HCs | Serum | TaqMan miRNA assays | Absolute quantification | Fan et al., 2015 |
| miR-148/152 family (Down) | 20 NSCLCs with BPD vs. 10 HCs | Serum | RT-qPCR RT-qPCR | U6 U6 let-7d/g/1 trio | Chen et al., 2015; Li et al., 2015; Powrózek et al., 2015 |
| miR-3662 (up) | 70 NSCLCs vs. 70 HCs | Serum | RT-qPCR | miR-39 | Wang et al., 2015 |
| miR-25, miR-214 miR-7 (up) | 100 NSCLCs vs. 100 HCs | Plasma | TaqMan MiRNA Arrays | U6snRNA ath-miR-159a | Wozniak et al., 2015 |
| A panel of 24 miRNAs (Relative expression) | 12 NSCLCs vs. 6 HCs | Exosomes | RT-PCR | mir-1228-3p | Giallombardo et al., 2016 |
| A panel of 8 miRNAs (Relative expression) | 38 NSCLCs, 16 patients with COPD, 16 HCs | Serum | TaqMan Low Density Arrays | U6 | Halvorsen et al., 2016 |

NSCLCs, NSCLC patients; HCs, healthy controls; RT-PCR, real-time reverse transcription quantitative polymerase chain reaction; COPD, chronic obstructive pulmonary disease; BPD, benign pulmonary diseases.
may contribute to the fact that different miRNA panels have been identified for NSCLC diagnosis. To begin with, different materials such as plasma/serum, whole blood, or exosomes used for cell-free miRNAs isolation make it possible that the quality and quantity of circulating miRNAs isolated by different researcher vary according to biological material types. Indeed, whole blood also contains a large amount of peripheral blood mononuclear cells (PBMCs) compared with serum or plasma. Intriguingly, a two-miRNA panel (miR-19b-3p and miR-29b-3p) arising from PBMCs have been developed by Jie Ma et al. to discriminate NSCLCs from healthy persons with 72.62% sensitivity and 82.61% specificity. This group also identified SCC, the major type of NSCLC using this two-miRNA panel, with 80.00% sensitivity and 89.86% specificity, which may imply that only focusing on serum-derived circulating miRNAs may not be enough to reflect a reliable result in terms of NSCLC diagnosis based on circulating miRNA detection (Ma et al., 2015). In addition, the inconsistency of the methods used for data analysis should also be considered to account for the existence of various miRNA-panels. As shown in Table 1, internal controls such as U6 and miR-39 have been used for the normalization of miRNA expression. Unfortunately, the high variability of non-coding RNAs including rRNAs, U6 snRNA and snORNs in the plasma microvesicles and their readily degradation in serum have been reported, which indicates that such non-coding RNAs may be inappropriate as endogenous controls (Chen et al., 2008). On a whole, more validations on the whole blood are warranted to identify circulating miRNA biomarkers that are of diagnostic value, coupled with a uniform and reliable internal control for data analysis. CTCs are another type of “liquid biopsy” ideal for the diagnosis of NSCLC. Several issues remain to be addressed with respect to CTC enrichment and detection. Firstly, the platform of CTC detection technology combining marker-dependent (Cell Search) and marker-independent approaches (Isolation by size of epithelial tumor cells) has proven to be more sensitive than either of the two methods alone could be (Krebs et al., 2012). In addition, CTC-associated miRNAs, such as miR-21, can be applied to detect CTCs with an EMT phenotype (Ortega et al., 2015). We may hypothesize here CTC-associated miRNAs are likely to contain a larger amount of information underlying NSCLC cases, not merely being used as a marker for detection of CTCs. On the whole, future validation about such work is warranted before routine clinical applications are available.

AUTHOR CONTRIBUTIONS

LC, WC, and SW: Contributed the research concept and design; Moreover, LC: Finished critical revision of this article; JH: Finished the collection and assembly of data, and then she wrote the article; FM: Finished the drawing of the figure in this article.

ACKNOWLEDGMENTS

I would like to acknowledge that this project is supported by the Health and Medical Research Fund (HMRF, Project No. 02131026).

REFERENCES

Alix-Panabieres, C., and Pantel, K. (2013). Circulating tumor cells: liquid biopsy of cancer. *Clin. Chem.* 59, 110–118. doi: 10.1373/cclinchem.2012.194258

Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., et al. (2004). Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. *Clin. Cancer Res.* 10, 6897–6904. doi: 10.1158/1078-0432.CCR-04-0378

Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruff, I. K., Pritchard, C. C., Gibson, D. F., et al. (2011). Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc. Natl. Acad. Sci. U.S.A.* 108, 5003–5008. doi: 10.1073/pnas.1019055108

Bartel, D. P., and Chen, C.-Z. (2004). Micro RNAs: a widespread influence on eukaryotic gene expression: the potentially widespread influence of metazoan microRNAs. *Nat. Rev. Genet.* 5, 396–400. doi: 10.1038/nrg1328

Benz, F., Roderburg, C., Vargas Cardenas, D., Vucur, M., Gautheron, J., Koch, A., et al. (2013). U6 is unsuitable for normalization of serum microRNA levels in patients with sepsis or liver fibrosis. *Exp. Mol. Med.* 45, e42. doi: 10.1038/emmm.2013.81

Bianchi, F., Nicassio, F., Marzi, M., Belloni, E., Dall’olio, V., Bernard, L., et al. (2011). A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage cancer. *EMBO Mol. Med.* 3, 495–503. doi: 10.1002/emmm.201100154

Boeri, M., Verri, C., Conte, D., Roz, L., Modena, P., Facchetti, F., et al. (2011). MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. *Proc. Natl. Acad. Sci. U.S.A.* 108, 3713–3718. doi: 10.1073/pnas.110988108

Boyerinas, B., Park, S. M., Hau, A., Murmann, A. E., Peter, M. E. (2010). The role of let-7 in cell differentiation and cancer. *Endocr. Relat. Cancer* 17, F19–F36. doi: 10.1677/erc-09-0184

Chang, J., Nicolas, E., Marks, D., Sander, C., Lerro, A., Buendia, M. A., et al. (2004). miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. *RNA Biol.* 1, 106–113. doi: 10.4161/rna.1.2.1066

Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., et al. (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res.* 18, 997–1006. doi: 10.1038/cr.2008.282

Chen, X., Wang, X., He, H., Liu, Z., Hu, J. F., and Li, W. (2015). Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer. *PLoS ONE* 10:e0126276. doi: 10.1371/journal.pone.0126276

Choudhury, N. R., and Michlewski, G. (2012). Terminal loop-mediated control of microRNA biogenesis. *Biochem. Soc. Trans.* 40, 789–793. doi: 10.1042/BST20120053

Collino, F., Deregibus, M. C., Bruno, S., Sterpone, L., Aghem, G., Violton, L., et al. (2010). Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of microRNAs. *PLoS ONE* 5:e11803. doi: 10.1371/journal.pone.0011803

Dou, H., Wang, Y., Su, G., and Zhao, S. (2015). Decreased plasma let-7c and miR-152 as noninvasive biomarker for non-small-cell lung cancer. *Int. J. Clin. Exp. Med.* 8, 9291–9298.

Fan, L., Qi, H., Teng, J., Su, B., Chen, H., Wang, C., et al. (2015). Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer. *Tumour Biol.* 37, 7777–7784. doi: 10.1007/s13277-015-4608-3

Gao, W., Liu, L., Xu, L., and Shu, Y. (2011). Circulating microRNAs: possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma. *Clin. Lung Cancer* 12, 14–17. doi: 10.3816/CLC.2011.n.001

Gherzi, R., Chen, C. Y., Trabucchi, M., Ramos, A., and Briata, P. (2010). The role of KSRP in miRNA decay and microRNA precursor maturation. *Wiley Interdiscip. Rev. RNA* 1, 230–239. doi: 10.1002/wrna.2
Giallombardo, M., Chacartegui Borrás, J., Castiglia, M., Van Der Steen, N., Mertens, I., Pauwels, P., et al. (2016). Exosomal miRNA analysis in Non-small Cell Lung Cancer (NSCLC) patients’ plasma through spcr: a feasible liquid biopsy tool. J. Vis. Exp. doi: 10.3791/53900

Halvorsen, A. R., Bjaanaa, M., LeBlanc, M., Holm, A. M., Bolstad, N., Rubio, L., et al. (2016). A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer. Oncotarget 7, 37250–37259. doi: 10.18632/oncotarget.9363

Hansson, A., Wagner, J., Gorges, T. M., Tzenzer, A., Uzunoglu, F. G., Driemel, C., et al. (2016). Characterization of different CTC subpopulations in non-small cell lung cancer. Sci. Rep. 6:28010. doi: 10.1038/srep28010

Harb, W., Fan, A., Tran, T., Danila, D. C., Keys, D., Schwartz, M., et al. (2013). Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay. Trans. Oncol. 6, 528–538. doi: 10.1593/tho.13367

Hardingham, J. E., Kotaske, D., Farmer, B., Butler, R. N., Mi, J.-X., Sage, R. E., et al. (1993). Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction. Cancer Res. 53, 3455–3458.

Haus, D. L., Nguyen, H. X., Gold, E. M., Kamei, N., Perez, H., Moore, H. D., et al. (2014). CD133-enriched Xeno-free human embryonic-derived neural stem cells expand rapidly in culture and do not form teratomas in immunodeficient mice. Stem Cell Res. 13, 214–226. doi: 10.1016/j.scr.2014.06.008

Hou, J.-M., Greystoke, A., Lancashire, L., Cumings, J., Ward, T., Board, R., et al. (2009). Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am. J. Pathol. 175, 808–816. doi: 10.2353/apth.2009.090078

Huang, Y. (2012). A mirror of two faces: Lin28 as a master regulator of gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Proc. Natl. Acad. Sci. U.S.A. 109, 303, 95–98. doi: 10.1073/pnas.0804549105

Jemal, A., Kwon, Y., Zhan, M., Mann, D. L., Stass, S. A., and Jiang, F. (2015). Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer. Lab. Invest. 95, 1197–1206. doi: 10.1038/labinvest.2015.88

Ma, J., Liu, S., and Wang, Y. (2014). MicroRNA-21 and multiple myeloma: small molecule and big med. Mol. Oncol. 3, 94. doi: 10.1002/1758-1076.12032-01109-5

Man, Y., Cao, L., Jin, S., Xu, G., Pan, B., Shang, L., et al. (2014). Newly identified biomarkers for detecting circulating tumor cells in lung adenocarcinoma. Tuhoku J. Exp. Med. 234, 29–40. doi: 10.1620/tjem.234.29

Markou, A., Sourvinou, I., Vorkas, P. A., Yousef, G. M., and Lianidou, E. (2013). Clinical evaluation of microRNA expression profiling in non-small cell lung cancer. Lung Cancer 81, 388–396. doi: 10.1016/j.lungcan.2013.05.007

Mascalchi, M., Falchini, M., Maddau, C., Salvianti, F., Nistri, M., Bertelli, E., et al. (2016). Prevalence and number of circulating tumour cells and microemboli at diagnosis of advanced NSCLC. J. Cancer Res. Clin. Oncol. 142, 195–200. doi: 10.1007/s00432-015-2123-1

Mayt, F., and Heinemann, U. (2013). Mechanisms of Lin28-mediated miRNA regulation—a structural and functional perspective. Int. J. Mol. Sci. 14, 16532–16555. doi: 10.3390/ijms14081874

Miclea, G., and Cáceres, J. F. (2010). Antagonistic role of Let-7 miRNAs in mammalian development and their clinical utility in lung cancer. J. Cancer Res. Clin. Oncol. 136(Suppl. 1), 8–12. doi: 10.1007/s00432-010-0882-y

Munielos-Romay, L., Vieito, M., Abalo, A., Nocel, M. A., Barón, F., Anido, U., et al. (2014). Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-line systemic treatment. Cancers (Basel). 6, 153–165. doi: 10.3390/cancers6010015

Nicolson, G., Guil, S., Semple, C. A., and Caceres, J. F. (2008). Posttranscriptional regulation of miRNAs harboring conserved terminal loops. Mol. Cell 32, 383–393. doi: 10.1016/j.molcel.2008.10.013

Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 105, 10513–10518. doi: 10.1073/pnas.0805494105

O'Flaherty, J. D., Gray, S., Richard, D., Fennell, D., O'Leary, J. J., Blackhall, F. H., et al. (2012). Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer 76, 19–25. doi: 10.1016/j.lungcan.2011.10.018

Okamura, K., Chung, W. J., and Lai, E. C. (2008). The long and short of inverted repeat genes in animals: microRNAs, mirtrons and hairpin RNAs. Cell Cycle 7, 2840–2845. doi: 10.4161/cc.7.18.6734

Ortega, F. G., Lorente, J. A., García Puche, J. L., Ruiz, M. P., Sanchez-Martin, R. M., de Miguel-Perez, D., et al. (2015). miRNA in situ hybridization in circulating tumor cells–MishCTC. Sci. Rep. 5:9207. doi: 10.1038/srep09207

Ozretić, L., Heukamp, L. C., Odenthal, M., and Buettner, R. (2012). The role of molecular diagnostics in cancer diagnosis and treatment. Onkol.茫茫25(5), 1–8. 12–12. doi: 10.1159/000334823

Park, J.-K., Lee, J. E., Esau, C., and Schmittgen, T. D. (2009). Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 38, e190–e199. doi: 10.1097/MPA.0b0131818a82e1

Parkinson, D. R., Dracopoli, N., Petty, B. G., Compton, C., Cristofanilli, M., DeSeriother, A., et al. (2012). Considerations in the development of circulating tumor cell technology for clinical use. J. Transl. Med. 10, 1. doi: 10.1186/1479-287X-10-5

Petrelli, D., Galetta, D., Rubini, V., Savino, E., Paradiso, A., Simone, G., et al. (2013). Molecular profiling of thin-prep FNA samples in assisting clinical management of non-small-cell lung cancer. Mol. Biotechnol. 54, 913–919. doi: 10.1007/s12033-012-9640-6

Pozor, T., Trawczyn, P., Kowalski, D., Winiarczyk, K., Olszyna-Semenova, M., and Melenowski, J. (2015). Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers. Trans. Res. 65, 315–323. doi: 10.1016/j.trsl.2015.05.009

Rabinovits, G., Gerczel-Taylor, C., Day, J. M., Taylor, D. D., and Klöcker, G. H. (2009). Exosomal microRNA: a diagnostic marker for lung cancer. Clin. Lung Cancer 10, 42–46. doi: 10.1016/j.clincr.2009.06.006

Ramon, P., Roseler, D., Jatkoe, T., Wu, X., Chen, G., Fan, H., et al. (2009). MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 69, 5776–5783. doi: 10.1158/0008-5472.CAN-09-0587
Scagliotti, G. V., Fossati, R., Torri, V., Crino, L., Giaccone, G., Silvano, G., et al. (2003). Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J. Natl. Cancer Inst. 95, 1453–1461. doi: 10.1093/jnci/djg059

Shen, J., Todd, N. W., Zhang, H., Yu, L., Lingxiao, X., Mei, Y., et al. (2011). Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab. Invest. 91, 579–587. doi: 10.1038/lab.2010.194

Si, M. L., Zhu, S., Wu, H., Lu, Z., Wu, F., and Mo, Y. Y. (2007). miR-21-mediated neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 19, 1116–1122. doi: 10.1038/mt.2011.48

Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., et al. (2011). International association for the study of lung cancer/American Thoracic Society/European Respiratory Society multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 6, 244–285. doi: 10.1097/JTO.0b013e318206a221

Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., and Lötvall, J. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–659. doi: 10.1038/ncb1596

Vickers, K. C., Palmsano, B. T., Shoucri, B. M., Shamburek, R. D., and Remaley, A. T. (2011). MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13, 423–433. doi: 10.1038/ncb2210

Volinia, S., Calin, G. A., Liu, C. G., Ambre, S., Cimmino, A., Petrocca, F., et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 103, 2257–2261. doi: 10.1073/pnas.0510565103

Wang, K., Zhang, S., Weber, J., Baxter, D., and Galas, D. J. (2010). Export of microRNAs and microRNA-protective protein by mammalian cells. Nucl. Acids Res. 38, 7248–7259. doi: 10.1093/nar/gkq601

Wang, R. J., Zheng, Y. H., Wang, P., and Zhang, J. Z. (2015). Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int. J. Clin. Exp. Pathol. 8, 765–771.

Westholm, J. O., and Lai, E. C. (2011). Mirtrons: microRNA biogenesis via splicing. Biochemic 93, 1897–1904. doi: 10.1016/j.biochem.2011.06.017

Wood, D. E., Eapen, G. A., Ettinger, D. S., Hou, L., Jackman, D., Kazerouni, E., et al. (2012). Lung cancer screening. J. Natl. Compr. Cancer Netw. 10, 240–265.

Wonnia, M. B., Scelo, G., Muller, D. C., Mukeria, A., Zaridze, D., and Brennan, P. (2013). Circulating microRNAs as non-invasive biomarkers for early detection of non-small-cell lung cancer. PLoS ONE 10:e0123506. doi: 10.1371/journal.pone.0123506

Wu, S., Liu, S., Liu, Z., Huang, J., Pu, X., Li, J., et al. (2015). Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS ONE 10:e0123976. doi: 10.1371/journal.pone.0123976

Yang, X., Zeng, Y., Yang, R., Xu, H., Chen, Z., Zhong, J., et al. (2014). U6 is not a suitable endogenous control for the quantification of circulating microRNAs. Biochem. Biophys. Res. Commun. 454, 210–214. doi: 10.1016/j.bbrc.2014.10.064

Yang, M., Shen, H., Qiu, C., Ni, Y., Wang, L., Dong, W., et al. (2013). High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur. J. Cancer 49, 604–615. doi: 10.1016/j.ejca.2012.09.031

Young, R., Palailer, E., Billiot, F., Drusch, F., Barthelemy, A., Oulhen, M., et al. (2012). Circulating tumor cells in lung cancer. Acta Cytol. 56, 655–660. doi: 10.1159/000345182

Zandberga, E., Kozirovskis, V., Abols, A., Andrejeva, D., Purkalne, G., and Line, A. (2013). Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer. Genes Chromosomes Cancer 52, 356–369. doi: 10.1002/gcc.22032

Zernecke, A., Bidzhekov, K., Noels, H., Shagdarsuren, E., Gan, L., Denecke, B., et al. (2009). Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci. Signal. 2, ra81-ra81. doi: 10.1126/scisignal.2006100

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Hou, Meng, Chan, Cho and Wong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.